Scleroderma Foundation increases research funding by more than 100%

By Jenni Spinner

- Last updated on GMT

(Aneese/iStock via Getty Images)
(Aneese/iStock via Getty Images)
The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.

In alignment with the June 29 commemoration of World Scleroderma Day, the Scleroderma Foundation announced it has increased its peer-reviewed scientific research funding to $2.723m USD each year. In addition, the group is increasing the amount of its individual awards to $200,000.

The changes are effective for the upcoming 2022 grant funding cycle, with a proposal submission deadline extended from September 15 to September 30. The increase includes specific requests for proposals covering two key areas

  • scleroderma-related lung disease research
  • pediatric scleroderma

According to the foundation, a specific, donor-funded grant of $200,000 is expected to be awarded to an established investigator conducting scleroderma-related lung disease research.  Pediatric-scleroderma research is earmarked for up to $500,000 in awards and is open to submissions from new and established investigators.

Robert Riggs, CEO of the Scleroderma Foundation, said the group’s efforts to fund research, even in the face of economic hardship, is essential to pursue treatment of the rare disease.

The need to accelerate the pace of discovery in scleroderma research is urgent​," Riggs commented. “We are proud of our leadership role in advancing scientific discovery and doing so with the integrity of the peer-review process​."

The group’s Peer-Review Research Committee is made up of medical and research experts from across the US. According to the Scleroderma Foundation, the committee utilizes the same merit-based scoring system as the one used by the National Institutes of Health.

Scleroderma is a rare disease that impacts the human body’s connective tissue as well as the vascular system. Typically considered an autoimmune rheumatic disease, the disease causes an overproduction of collagen, or fibrosis, that hardens tissue and damages organs.  Commonly affecting the skin, scleroderma also affects internal organs; to date, researchers do not know the cause, and currently there are no approved treatments or cures.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars